Anthropic Confirms Bay Area Wet Lab for Biology Experiments
TL;DR
- Reuters broke the story as an exclusive; TechCrunch, CNBC, The Next Web, and Yahoo Finance confirmed or followed within 24 hours.
- Anthropic's 'not for drug discovery' disclaimer conflicts with confirmed Novo Nordisk and Bristol-Myers Squibb partnerships and the $400M Coefficient Bio drug-tools acquisition.
- The Life Sciences Verification Program creates tiered model access that functions simultaneously as biosecurity risk mitigation and a commercial gatekeeping mechanism.
Anthropic has a wet biology lab in the San Francisco Bay Area, and its head of life sciences confirmed it this week to TechCrunch.
"We believe that to do biology, the final test is still, and will be for a while, in real lab work," said Eric Kauderer-Abrams, Anthropic's head of life sciences. "We absolutely are doing that today."
The company has not disclosed the lab's size, staff count, opening date, or biosafety level. Kauderer-Abrams said the focus is fundamental biology rather than drug discovery, and that some biological work still goes to outside partners. Asked how far the lab has gone toward letting machines run experiments, he said the company is "in the very early innings." On biosafety, he said, "we're always balancing these things."
The lab sits on top of an acquisition. In April, Anthropic paid approximately $400 million in stock for Coefficient Bio, a stealth startup with fewer than ten employees. Life sciences is now among Anthropic's largest operational areas by headcount and spending, and recent recruiting includes a procurement lead and a biochemical specialist. Novo Nordisk, Genentech and Bristol Myers Squibb are named Claude Science customers, and Novartis CEO Vas Narasimhan joined Anthropic's Long-Term Benefit Trust in April.
Alongside the lab confirmation, Anthropic launched a Life Sciences Verification Program this week, giving vetted biology researchers access to its most advanced models. It is the third Anthropic story we've logged in the last two days, alongside the company's $1B pledge with Accenture to embed AI evaluators.
What others are reporting
-
Reuters Read →
The originating exclusive: two anonymous sources confirmed the lab, Reuters also broke the Novartis board seat and $400M Coefficient Bio acquisition in the same report.
We believe that to do biology, the final test is still and will be for a while in real lab work. We absolutely are doing that today.
-
Quartz Read →
Adds confirmed pharma partnerships with Novo Nordisk and Bristol-Myers Squibb and frames Anthropic's rare-disease targeting as deliberate avoidance of incumbent pharma commercial turf.
We believe that to do biology, the final test is still and will be for a while in real lab work.
-
The Next Web Read →
Highlights the structural tension between Anthropic's public bioweapons safety warnings and its simultaneous quiet investment in physical biology capabilities.
We believe that to do biology, the final test is still and will be for a while in real lab work.
-
Newsquawk Read →
Frames the tiered verification scheme as a potential precursor to regulatory scrutiny, noting voluntary gating may not satisfy biosecurity policy requirements.
Access-gating programmes of this kind from frontier AI developers follow a now-familiar pattern: controlled tiers for sensitive domains.
-
Breitbart Read →
Carries investor Chamath Palihapitiya's critique that biosafety warnings function as a competitive moat, juxtaposed against Anthropic's biological expansion and simultaneous AI slowdown calls.
Shared on Bluesky by 2 AI experts
-
Mark Riedl @markriedl.bsky.social
Anthropic: you are not sufficiently afraid of AI. Here: let me help you with that techcrunch.com/2026/09/18/a...
View on Bluesky →
Originally reported by techcrunch.com
Read the original article →Original headline: Anthropic Runs Bay Area Wet Lab for AI-Directed Biology Experiments, Launches Life Sciences Verification Program